Critical Analysis: Genocea Biosciences (NASDAQ:GNCA) & OKYO Pharma (NASDAQ:OKYO)

Genocea Biosciences (NASDAQ:GNCA) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.

Valuation and Earnings

This table compares Genocea Biosciences and OKYO Pharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	$1.91 million	0.00	-$33.20 million	($0.61)	N/A
OKYO Pharma	N/A	N/A	-$16.83 million	N/A	N/A

OKYO Pharma has lower revenue, but higher earnings than Genocea Biosciences.

Volatility & Risk

Genocea Biosciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Genocea Biosciences and OKYO Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genocea Biosciences	0	0	0	0	0.00
OKYO Pharma	0	0	1	0	3.00

OKYO Pharma has a consensus target price of $7.00, indicating a potential upside of 560.38%. Given OKYO Pharma’s stronger consensus rating and higher probable upside, analysts plainly believe OKYO Pharma is more favorable than Genocea Biosciences.

Profitability

This table compares Genocea Biosciences and OKYO Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	-182.88%	-62.76%
OKYO Pharma	N/A	N/A	N/A

Insider and Institutional Ownership

0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 40.5% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

OKYO Pharma beats Genocea Biosciences on 8 of the 10 factors compared between the two stocks.

About Genocea Biosciences

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.